Publication details

Konsolidační léčba brentuximab vedotinem u pacientů s relabujícím/refrakterním klasickým Hodgkinovým lymfomem po provedení autologní transplantace hematopoetických kmenových buněk v České republice

Title in English Brentuximab vedotin consolidation therapy after autologous stem cell transplantation in relapsed/refractory classic Hodgkin lymphoma patients in the Czech Republic
Authors

MICHALKA Jozef KRÁL Zdeněk MARKOVÁ Jana GAHÉROVÁ Ľubica MACO Mária PROCHÁZKA Vít JANÍKOVÁ Andrea KOŘEN Jan SÝKOROVÁ Alice ŠTĚPÁNKOVÁ Pavla STEINEROVÁ Kateřina MOHAMMAD Lekaa ĎURAŠ Juraj VELACKOVÁ Barbora DOLEŽAL Tomáš BENEŠOVÁ Kateřina LUKÁŠOVÁ Marie MÓCIKOVÁ Heidi

Year of publication 2023
Type Article in Periodical
Magazine / Source Onkologie
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.onkologiecs.cz/artkey/xon-202304-0009_konsolidacni_lecba_brentuximab_vedotinem_u_pacientu_s_relabujicim_refrakternim_klasickym_hodgkinovym_lymfomem_p.php
Doi http://dx.doi.org/10.36290/xon.2023.051
Keywords Hodgkin lymphoma; autologous transplantation; consolidation therapy; brentuximab vedotin
Attached files
Description The results from the clinical trial AETHERA showed that consolidation therapy with brentuximab vedotin after high-dose chemotherapy followed by autologous stem cell transplantation increases progression free survival in high-risk patients with relapsed/refractory classic Hodgkin lymphoma. In this multicenter retrospective analysis from seven hematological centers in the Czech republic we have analysed real-life data of 39 patients treated between January 2015 and December 2021. Brentuximab vedotin was not administered in the previous treatment and the patients were at increased risk of subsequent lymphoma relapse with at least one defined risk factor. The median cycles of brentuximab vedotin administered was 8 (1-16), 82 % of the patients achieved complete remission during the treatment. The median follow-up was 28 months, the 2-year progression-free survival and overal survival were 66,2 % (95 % CI 0,52-0,85) and 95 % (95 % CI 0,82-1,00), respectively. The most common reason for treatment discontinuation was completion of 16 cycles administered (20,5 %) relapse/progression of the lymphoma (15,4 %) and symptomatic peripheral neuropathy as well, that was observed in various severity grades in 38,5 % patients overall. Our data have confirmed efficacy and safety of brentuximab vedotin consolidation therapy in the real-life clinical practice.

You are running an old browser version. We recommend updating your browser to its latest version.

More info